Stivarga Regorafenib Tablets Patient Information Leaflet

This document provides the patient information leaflet for Stivarga (Regorafenib) 40mg tablets, detailing indications, dosage instructions, side effects…


Stivarga Regorafenib Tablets Patient Information Leaflet - cover page
Brand
Bayer
Document type
User Manual
Language
Chinese
Pages
21
File format
PDF
File size
418 KB
Published
21 October, 2026
Updated
21 October, 2026
MD5 checksum
E7D8688CBE0C57F720964D62BEF91091

About this manual

The document is a Chinese language package insert for Regorafenib Tablets, marketed under the brand name Stivarga. It outlines the drug's usage for treating metastatic colorectal cancer (mCRC), gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma (HCC) in patients who have previously received specific therapies.

Key sections include detailed dosage recommendations of 160mg daily, administration instructions requiring a low-fat breakfast, and extensive guidance on dose adjustments for adverse reactions such as hand-foot skin reaction (HFSR) and liver toxicity. The text also lists common side effects like pain, fatigue, diarrhea, and hypertension based on clinical trial data. This manual is written in Chinese.

What's inside

  • 药品名称
  • 适应症
  • 规格
  • 用法用量
  • 剂量调整及特殊使用说明
  • 不良反应
  • 注意事项

Frequently asked questions

What is the recommended dosage for Regorafenib?

The recommended dose is 160mg (4 tablets) once daily, taken orally on days 1-21 of a 28-day cycle.

When should Regorafenib tablets be taken?

The tablet should be swallowed whole with water immediately after a low-fat breakfast (30% fat content) at the same time each day.

Download PDF (418 KB)

More Bayer Manuals


View all Bayer manuals →